<DOC>
	<DOC>NCT00199264</DOC>
	<brief_summary>To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of albaconazole, as a single oral dose, in women affected by acute non-complicated vulvovaginitis due to Candida spp.</brief_summary>
	<brief_title>Efficacy Vulvovaginitis Candida</brief_title>
	<detailed_description>Multi-center, open-label, randomized study, controlled with fluconazole.</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vulvovaginitis</mesh_term>
	<criteria>Ambulatory patients over 18 years of age, with a vaginal score sum Â³ 2 and KOH fresh examination positive for yeasts (hyphae, pseudohyphae). The diagnosis must be later confirmed with a positive Candida spp. culture. Patients with recurrent disease, prior treatment with antifungal agents within the last 7 days, immunosuppression, pregnant or lactating women, other vulvovaginal diseases, other systemic diseases, hypersensitivity to azole derivatives.Number of patients: 78 patients included to obtain 60 evaluable patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>antifungal oral therapy</keyword>
	<keyword>efficacy acute candidiasis vulvaginitis</keyword>
</DOC>